Found: 28
Select item for more details and to access through your institution.
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
- Published in:
- 2017
- By:
- Publication type:
- journal article
The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 174, n. 1, p. 271, doi. 10.1007/s10549-018-5054-x
- By:
- Publication type:
- Article
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers—an extrapolation framework.
- Published in:
- Therapeutic Advances in Medical Oncology, 2024, p. 1, doi. 10.1177/17588359241273062
- By:
- Publication type:
- Article
Next-generation sequencing, should I use anti-HER2 therapy for HER2 -amplified tumors off-label? Illustrating an extrapolation framework.
- Published in:
- Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221112822
- By:
- Publication type:
- Article
Reply to Q. Wu et al.
- Published in:
- 2019
- By:
- Publication type:
- Letter to the Editor
Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2018, v. 14, n. 3, p. 141, doi. 10.1111/ajco.12838
- By:
- Publication type:
- Article
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46008-1
- By:
- Publication type:
- Article
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211049639
- By:
- Publication type:
- Article
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer.
- Published in:
- Therapeutic Advances in Medical Oncology, 2021, p. 1, doi. 10.1177/17588359211049639
- By:
- Publication type:
- Article
When do patient reported quality of life indicators become prognostic in breast cancer?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Pathways to diagnosis of non-small cell lung cancer: a descriptive cohort study.
- Published in:
- NPJ Primary Care Respiratory Medicine, 2019, v. 29, n. 1, p. 1, doi. 10.1038/s41533-018-0113-7
- By:
- Publication type:
- Article
When is a GIST not a GIST? A case report of synchronous metastatic gastrointestinal stromal tumor and fibromatosis.
- Published in:
- 2009
- By:
- Publication type:
- Case Study
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00698-4
- By:
- Publication type:
- Article
Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis.
- Published in:
- Therapeutic Advances in Medical Oncology, 2018, v. 10, n. 1, p. 1, doi. 10.1177/1758835918788500
- By:
- Publication type:
- Article
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
- Published in:
- International Journal of Cancer, 2014, v. 135, n. 3, p. 731, doi. 10.1002/ijc.28698
- By:
- Publication type:
- Article
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
- Published in:
- British Journal of Cancer, 2024, v. 130, n. 3, p. 425, doi. 10.1038/s41416-023-02528-z
- By:
- Publication type:
- Article
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
- Published in:
- British Journal of Cancer, 2023, v. 129, n. 3, p. 475, doi. 10.1038/s41416-023-02311-0
- By:
- Publication type:
- Article
Criteria-based curation of a therapy-focused compendium to support treatment recommendations in precision oncology.
- Published in:
- NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00194-z
- By:
- Publication type:
- Article
Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
- Published in:
- JAMA Network Open, 2020, v. 3, n. 9, p. e2011809, doi. 10.1001/jamanetworkopen.2020.11809
- By:
- Publication type:
- Article
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 1, p. 90, doi. 10.1080/0284186X.2019.1674452
- By:
- Publication type:
- Article
The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 1, p. 96, doi. 10.1080/0284186X.2019.1670354
- By:
- Publication type:
- Article
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.
- Published in:
- Acta Oncologica, 2020, v. 59, n. 1, p. 20, doi. 10.1080/0284186X.2019.1656342
- By:
- Publication type:
- Article
Novel Concept of Replacing Antibiotic in Surgical Removal of Impacted Mandibular Third Molar.
- Published in:
- International Medical Journal, 2013, v. 20, n. 4, p. 470
- By:
- Publication type:
- Article
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 7, p. 1449, doi. 10.1002/cncr.34085
- By:
- Publication type:
- Article
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 14, p. 2432, doi. 10.1002/cncr.33517
- By:
- Publication type:
- Article
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
- Published in:
- 2013
- By:
- Publication type:
- journal article
Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2013, v. 105, n. 9, p. 595, doi. 10.1093/jnci/djt072
- By:
- Publication type:
- Article